JANX
Janux Therapeutics, Inc.
There isn't enough reported data to score JANX yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
JANX Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Under pressure | |
| Unavailable |
JANX's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
JANX PE Valuation
JANX has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
JANX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect JANX's losses to grow, with revenue declining. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
JANX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.59 | +$0.09 |
| Q2 2026 | -$1.64 | +$0.16 |
| Q1 2026 | -$1.84 | -$0.48 |
| Q4 2025 | -$1.83 | -$0.55 |
| Q3 2025 | -$1.68 | -$0.53 |
| Q2 2025 | -$1.80 | -$0.91 |
| Q1 2025 | -$1.36 | -$0.16 |
| Q4 2024 | -$1.28 | +$0.04 |
JANX lost $1.59 per share over the past year, about the same as its loss the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over JANX on earnings quality, reporting a profit while its opponent remains loss making.
JANX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $9.3M | -7.1% |
| Q3 2025 | $10M | +2178% |
| Q3 2024 | $439K | -83% |
| Q2 2024 | $8.9M | +742% |
| Q1 2024 | $1.3M | -39% |
| Q4 2023 | $2.5M | -13% |
| Q3 2023 | $2.5M | +39% |
| Q2 2023 | $1.1M | -55% |
JANX's revenue is growing: $9M last quarter, down 7.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -337% | +16 points |
| Q2 2026 | -309% | N/A |
| Q1 2026 | -917% | N/A |
| Q3 2025 | -353% | +7812 points |
| Q3 2024 | -8164% | -7536 points |
| Q2 2024 | -155% | +1808 points |
| Q1 2024 | -1610% | -620 points |
| Q4 2023 | -656% | -14 points |
JANX's operating margin was −337% last quarter, up 7828 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over JANX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over JANX on profitability, with a higher operating margin.
JANX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$25.2M | -$12.2M |
| Q2 2026 | $12.3M | +$36.6M |
| Q1 2026 | -$12.6M | +$4.8M |
| Q4 2025 | -$28.6M | -$11.9M |
| Q3 2025 | -$12.9M | -$10.7M |
| Q2 2025 | -$24.3M | -$14.2M |
| Q1 2025 | -$17.4M | -$2.4M |
| Q4 2024 | -$16.8M | -$6.4M |
JANX has burned cash in almost every quarter: −$54M over the past year, against −$71M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over JANX on cash generation, producing positive trailing cash flow while its opponent burns cash.
JANX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +153K shares |
| 1 year | +1.7% | +1.1M shares |
| 3 years | +38% | +17.4M shares |
| 5 years | +529% | +53.1M shares |
| Available history | +406% | +50.6M shares |
JANX has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
JANX Net Leverage
JANX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
JANX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.3 | Neutral |
| Stochastic | 34.0 | Neutral |
JANX's weekly RSI is 35 (neutral) and its Stochastic is 34 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
JANX PE vs Healthcare Sector
JANX has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
JANX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $16.4 | 30% below |
| 20 week MA | $16.6 | 31% below |
| 50 week MA | $15.1 | 24% below |
| 100 week MA | $22.7 | 49% below |
| 200 week MA | $24.7 | 53% below |
JANX is in a downtrend: it's below all five of its weekly moving averages, and 53% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over JANX on trend strength, trading above more of its moving averages.
JANX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $25.2 | $21.4 | -15% |
| 2022 | $21.4 | $11.9 | -45% |
| 2023 | $11.9 | $10.7 | -9.5% |
| 2024 | $10.7 | $54.1 | +404% |
| 2025 | $54.1 | $14.3 | -74% |
| 2026 YTD | $14.3 | $11.5 | -19% |
JANX's yearly returns have swung widely, from +404% in 2024 to −74% in 2025. It's down 19% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over JANX on returns for 2026, with the stronger performance.